Legal & General Group
NGNE icon

Legal & General Group’s Neurogene NGNE Stock Holding History

Legal & General Group’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18.1K Hold
898
– – ﹤0.01% 2994
2025
Q4 		$18.5K Hold
898
– – ﹤0.01% 3060
2025
Q3 		$15.6K Hold
898
– – ﹤0.01% 3150
2025
Q2 		$13.4K Sell
898
-332
-27% -$5.21K ﹤0.01% 3172
2025
Q1 		$14.4K Buy
1,230
+208
+20% +$3.61K ﹤0.01% 3060
2024
Q4 		$23.4K Hold
1,022
– – ﹤0.01% 2970
2024
Q3 		$42.9K Hold
1,022
– – ﹤0.01% 2809
2024
Q2 		$37.2K Buy
+1,022
New +$36K ﹤0.01% 2835
2022
Q2 		– Sell
-152
Closed -$6K – 3610
2022
Q1 		$6K Hold
152
– – ﹤0.01% 3489
2021
Q4 		$15K Sell
152
-389
-72% -$47.4K ﹤0.01% 3366
2021
Q3 		$78K Buy
541
+332
+159% +$50.8K ﹤0.01% 2893
2021
Q2 		$39K Sell
209
-35
-14% -$7.74K ﹤0.01% 3033
2021
Q1 		$60K Sell
244
-10
-4% -$2.56K ﹤0.01% 2763
2020
Q4 		$71K Hold
254
– – ﹤0.01% 2687
2020
Q3 		$61K Sell
254
-49
-16% -$11.9K ﹤0.01% 2625
2020
Q2 		$100K Buy
+303
New +$79K ﹤0.01% 2534

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Legal & General Group's NGNE Position: Q1 2026 in Review

Legal & General Group held its Neurogene (NGNE) position steady in Q1 2026 at 898 shares worth $18.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2994.

Legal & General Group first reported a position in NGNE in Q2 2020 and has held it in 16 quarters since. The position peaked at $100K in Q2 2020. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Legal & General Group held 898 shares of Neurogene worth $18.1K as of Q1 2026.
  • Legal & General Group left its Neurogene share count unchanged in Q1 2026.
  • Neurogene made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #2994 holding.
  • Legal & General Group first reported a position in Neurogene in Q2 2020 and has held it in 16 quarters since.
  • Legal & General Group's Neurogene position peaked at $100K in Q2 2020.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.